Ivana M Ilickovic1, Slobodan M Jankovic2, Aleksandar Tomcuk3, Jovo Djedovic3. 1. Regulatory, Pharmacovigilance and Quality Department, Farmegra Ltd, Podgorica, Montenegro. 2. Department of Pharmacology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia. 3. Specialised Hospital for Psychiatric Diseases, Dobrota, Kotor, Montenegro.
Abstract
OBJECTIVES: The aim of this study was to evaluate implementation of services provided by a clinical pharmacist for long-term-hospitalised patients with schizophrenia in a pharmaceutical-care-naive developing country. METHOD: This was a prospective, healthcare-system, interventional, 'before-and-after' study. Long-term (≥6 months) inpatients with schizophrenia were included. A clinical pharmacist reviewed the full patient notes, identified drug-related problems (DRPs), and proposed interventions using a DRP Registration Form (PCNE classification V6.2). Acceptance rate and outcomes of interventions were assessed. RESULTS: For 49 patients, 71 DRPs were identified, ranging from one to four problems/patient (1.43±0.68), predominantly related to tolerability and treatment effectiveness. The DRPs were mostly caused (N=184) by inappropriate drug selection (64%) or dose (23.4%): too many drugs for indication (N=33); a non-cost-effective choice (N=29); inappropriate combination (N=27); an inappropriate drug (N=23); lack of therapeutic drug monitoring (N=14); subtherapeutic (N=13) or supratherapeutic (N=11) dosing. Excessive treatment duration was observed for 14 DRPs. The clinical pharmacist proposed 182 interventions (70% at the drug level): discontinuation of medication (N=58); dosage change (N=35); other interventions (monitoring) (N=35); a change of drug (N=18) or instructions for use (N=9); and/or introduction of a new drug (N=7). Physicians accepted 91 interventions and refused 36. Finally, 38 DRPs were solved (25 completely and 13 partially), for 25 a solution was either not needed or not possible, and, for eight, the outcome was not known. CONCLUSIONS: The study underlines the high potential for pharmaceutical care to improve prescribing practices in developing countries without shared pharmacist-physician decision-making.
OBJECTIVES: The aim of this study was to evaluate implementation of services provided by a clinical pharmacist for long-term-hospitalised patients with schizophrenia in a pharmaceutical-care-naive developing country. METHOD: This was a prospective, healthcare-system, interventional, 'before-and-after' study. Long-term (≥6 months) inpatients with schizophrenia were included. A clinical pharmacist reviewed the full patient notes, identified drug-related problems (DRPs), and proposed interventions using a DRP Registration Form (PCNE classification V6.2). Acceptance rate and outcomes of interventions were assessed. RESULTS: For 49 patients, 71 DRPs were identified, ranging from one to four problems/patient (1.43±0.68), predominantly related to tolerability and treatment effectiveness. The DRPs were mostly caused (N=184) by inappropriate drug selection (64%) or dose (23.4%): too many drugs for indication (N=33); a non-cost-effective choice (N=29); inappropriate combination (N=27); an inappropriate drug (N=23); lack of therapeutic drug monitoring (N=14); subtherapeutic (N=13) or supratherapeutic (N=11) dosing. Excessive treatment duration was observed for 14 DRPs. The clinical pharmacist proposed 182 interventions (70% at the drug level): discontinuation of medication (N=58); dosage change (N=35); other interventions (monitoring) (N=35); a change of drug (N=18) or instructions for use (N=9); and/or introduction of a new drug (N=7). Physicians accepted 91 interventions and refused 36. Finally, 38 DRPs were solved (25 completely and 13 partially), for 25 a solution was either not needed or not possible, and, for eight, the outcome was not known. CONCLUSIONS: The study underlines the high potential for pharmaceutical care to improve prescribing practices in developing countries without shared pharmacist-physician decision-making.
Authors: Wolfgang Gaebel; Stefan Weinmann; Norman Sartorius; Wolfgang Rutz; John S McIntyre Journal: Br J Psychiatry Date: 2005-09 Impact factor: 9.319
Authors: Anne Gerd Granas; Christian Berg; Vidar Hjellvik; Cecilie Haukereid; Arvid Kronstad; Hege S Blix; Bente Kilhovd; Kirsten K Viktil; Anne Marie Horn Journal: Pharm World Sci Date: 2010-04-21
Authors: Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller Journal: Schizophr Bull Date: 2009-12-02 Impact factor: 9.306
Authors: A L Yailian; E Huet; B Charpiat; O Conort; M Juste; R Roubille; M Bourdelin; J Gravoulet; C Mongaret; C Vermorel; P Bedouch; A Janoly-Duménil Journal: Int J Clin Pract Date: 2022-06-28 Impact factor: 3.149